Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04972721 · ClinicalTrials.gov registry record

SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial

A clinical trial of Obesity and Overweight, sponsored by Novo Nordisk A/S.

Completed
Registry status
3,439
Enrollment target
20
Study locations

NCT04972721: Completed study of Obesity and Overweight, sponsored by Novo Nordisk A/S.

NCT04972721 is a study of Obesity and Overweight that has completed, run by Novo Nordisk A/S. The registered enrollment target is 3,439 participants, above the 816-participant average among 1,053 other Obesity trials with a reported enrollment target (321% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04972721, a study of Obesity and Overweight, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
3,439 participants
Enrollment target
20
Study locations

Study Summary

Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial. SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends. SELECT-LIFE looks at the long-term effects of participants taking part in the SELECT trial including the trial medicine participants have been taking. When the SELECT trial ends, participants will no longer get the medicine participants got in the study, even if participants decide to take part in the SELECT-LIFE study. Participants will not get any specific treatment or medicine as part of the SELECT-LIFE study, and participants will be treated as participants normally would by their own doctor. The SELECT-LIFE study will last for up to 10 years after SELECT trial ends, and participants will be asked to fill in a questionnaire about their health every 6 months.

Conditions Studied

Obesity Overweight

Interventions

  • OTHER No treatment given

Study Locations (20)

São Paulo

  • Instituto de Pesquisa Clínica de Campinas - Campinas
  • CIP Centro Integrado de Pesquisas do Hospital de Base - São José do Rio Preto
  • CPQuali Pesquisa Clínica Ltda - São Paulo
  • CPCLIN - Centro de Pesquisas Clínicas - São Paulo
  • Instituto Dante Pazzanese de Cardiologia - São Paulo
  • Departamento de Gastroenterologia - HCFMUSP - São Paulo
  • Instituto do Coração - HCFMUSP - São Paulo
  • Master Centre for Brazil - Säo Paulo

Other

  • Master Centre for Algeria - Algiers
  • Master Centre for Argentina - Prov. de Buenos Aires
  • Instituto Brasil de Pesquisa Clinica - Rio de Janeiro

New Jersey

  • Master Centre for USA - Plainsboro

New South Wales

  • Master Centre for Australia - North Sydney

Estado de Bahia

  • Cárdio Pulmonar da Bahia - Salvador

Federal District

  • Hospital do Coração do Brasil - Brasília

Minas Gerais

  • Eurolatino Medical Research Center - Uberlândia

Paraná

  • Núcleo de Pesquisa Clínica S/S - Curitiba

Trial Details

FieldValue
Enrollment Target 3,439 participants
Start Date 2023-09-01
Est. Completion 2025-08-25

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04972721

The ClinicalTrials.gov registry entry for NCT04972721 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,439 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 816-participant average among 1,053 other Obesity trials with a reported enrollment target (321% higher). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which No treatment given is the first listed.

NCT04972721 reports 20 study locations spanning 11 distinct geographic areas - top geographies include São Paulo, Other, New Jersey.

Frequently Asked Questions

What is clinical trial NCT04972721 about?

NCT04972721 is a clinical study titled "SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial". Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial. SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends. SELECT-LIFE looks at the long-term effects of participants taking part in the SELECT trial incl...

What is the current status of trial NCT04972721?

This trial is currently completed. The enrollment target is 3,439 participants. The study started on 2023-09-01. Estimated completion is 2025-08-25.

What conditions does trial NCT04972721 study?

This clinical trial studies the following conditions: Obesity, Overweight.

What interventions are being tested in trial NCT04972721?

The interventions under investigation include: No treatment given (OTHER).

Who is sponsoring clinical trial NCT04972721?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04972721 being conducted?

This trial has 20 study locations across New Jersey, New South Wales, Estado de Bahia, Federal District, Minas Gerais. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Overweight

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.